Adrenaline (Epinephrine) Injector Prescription Guidelines - Summary of 2022 Updates

ASCIA Adrenaline (Epinephrine) Injector Prescription Guidelines have been updated in 2023 to provide the latest information to support the appropriate prescription and dose of adrenaline injectors for use in non-medical settings, for the emergency first aid treatment of potentially life-threatening severe allergic reactions (anaphylaxis).  The three main updates are outlined in this summary.

pdfASCIA HP Guidelines Adrenaline Injector Prescription UPDATES SUMMARY 202366.98 KB

UPDATE 1: ASCIA recommends the use of adrenaline as the first line treatment for anaphylaxis using either of the following two brands of adrenaline injectors:

  • EpiPen®  (150 and 300 microgram) - TGA approved and available in Australia on the PBS (up to two devices per prescription), and New Zealand (Pharmac listed since 1 February 2023).
  • Anapen® (150, 300 and 500 microgram) - TGA approved and available in Australia on the PBS (up to two devices per prescription).

If you do not want brand substitution, it is important to specify brand and tick box on PBS prescription. 

EpiPen® and Anapen® are also available without prescription.

UPDATE 2: Both EpiPen® and Anapen® devices are widely used in other countries. Multiple brands of devices are available in most countries, and this is important for the following reasons:

  • To ensure continued supply of life saving adrenaline, particularly if one brand has stock shortages.
  • To provide doctors with a choice of dose, who may prefer to prescribe a higher dose (500 microgram device) for people over 50kg.
  • A 500 microgram dose can potentially prevent the need for further doses of adrenaline (which is important due to increasing ambulance delays and many people only carrying one device).
  • To encourage suppliers to provide devices with longer shelf life.
  • To provide choice for consumers to access devices with points of difference to best suit their needs.

 UPDATE 3: ASCIA recommends the adrenaline injector doses listed below, which are consistent with several publications. These include the Acute Anaphylaxis Clinical Care Standard for Australia, Australian Prescriber Anaphylaxis Wallchart, Australian Immunisation Handbook and international recommendations from the World Allergy Organisation (WAO), Canada and the UK.  

Children 7.5-20kg (aged around one to five years):

  • EpiPen® Jr (150 microgram) or Anapen® 150 (Jr) (150 microgram)

Adults and children over 20kg (aged around five years or over):

  • EpiPen® (300 microgram) or Anapen® 300 (300 microgram)

Adults and children over 50kg (aged around twelve years or over):

  • New *Anapen® 500 (500 microgram) or Anapen® 300 (300 microgram) or EpiPen® (300 microgram).

*The dose of adrenaline in Anapen® 500 is consistent with the intramuscular injection (IMI) dose recommendations for people who weigh more than 50kg in the publications listed on

ASCIA guidelines should be used in conjunction with clinical judgement, with consideration of issues that include training on a new device and preference of device from the patient or their carer.

© ASCIA 2023 

Content updated January 2023 

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia